Safety of moxifloxacin as shown in animal and in vitro studies
- PMID: 16257310
- DOI: 10.1016/j.survophthal.2005.05.003
Safety of moxifloxacin as shown in animal and in vitro studies
Abstract
Topical treatment of ocular bacterial infection is practiced widely, and the choice of the antibacterial agent depends on the nature of the infection, including the susceptibility of the organism, the tissue affected, and the safety profile of the agent. Moxifloxacin is a fourth-generation fluoroquinolone approved for ophthalmic use as moxifloxacin ophthalmic solution 0.5% (VIGAMOX, Alcon, Fort Worth, TX). Moxifloxacin ophthalmic solution 0.5% is self-preserved at a near-neutral pH of 6.8. In treating ocular infection, the three important aspects of therapeutic control are potency, penetration of the drug to the target site, and safety of the drug and the drug product. Moxifloxacin ophthalmic solution 0.5% provides antibacterial potency and high penetration of target ocular tissues. The ocular and systemic safety profile of moxifloxacin compares favorably with those of other fluoroquinolone antimicrobial agents, with a low risk of recognized quinolone-related toxicity. In vitro studies of fluoroquinolones with human or rabbit corneal epithelial cells or keratocytes suggest that moxifloxacin is similar in cytotoxicity potential to other drugs of this family. Specialized in vivo corneal wound-healing studies draw little distinction between moxifloxacin-treated eyes and those treated with other fluoroquinolones. Repeated-dose topical ocular studies in rabbits and monkeys, with high concentrations (up to 3%) of moxifloxacin and at treatment durations and regimens well in excess of label-prescribed use, demonstrated a high safety margin for ocular and extraocular tissues. Cornea, the tissue with highest exposure, was found to be unaffected by these high exposures, with slit-lamp biomicroscopy, corneal thickness measurement, intraocular pressure, and specular microscopy of the corneal endothelium (monkeys only), and histologic evaluation showing no effects, as compared with controls. Moxifloxacin ophthalmic solution 0.5% affords superior efficacy and ocular tissue penetration, with a favorable safety profile.
Similar articles
-
In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.Surv Ophthalmol. 2005 Nov;50 Suppl 1:S16-31. doi: 10.1016/j.survophthal.2005.06.002. Surv Ophthalmol. 2005. PMID: 16257308 Review.
-
Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans.Surv Ophthalmol. 2005 Nov;50 Suppl 1:S32-45. doi: 10.1016/j.survophthal.2005.07.001. Surv Ophthalmol. 2005. PMID: 16257309 Review.
-
Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).Surv Ophthalmol. 2005 Nov;50 Suppl 1:S7-15. doi: 10.1016/j.survophthal.2005.05.002. Surv Ophthalmol. 2005. PMID: 16257313 Review.
-
Ophthalmic infections and their anti-infective challenges.Surv Ophthalmol. 2005 Nov;50 Suppl 1:S1-6. doi: 10.1016/j.survophthal.2005.05.001. Surv Ophthalmol. 2005. PMID: 16257307 Review.
-
Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model.Am J Ophthalmol. 2005 Sep;140(3):497-504. doi: 10.1016/j.ajo.2005.04.015. Am J Ophthalmol. 2005. PMID: 16083841
Cited by
-
Improved Ocular Bioavailability of Moxifloxacin HCl using PLGA Nanoparticles: Fabrication, Characterization, In-vitro and In-vivo Evaluation.Iran J Pharm Res. 2021 Summer;20(3):592-608. doi: 10.22037/ijpr.2021.114478.15054. Iran J Pharm Res. 2021. PMID: 34904011 Free PMC article.
-
Efficacy of topical moxifloxacin on therapeutic laparoscopy-induced wound healing: a double-blind, randomized clinical trial.BMC Surg. 2025 May 6;25(1):198. doi: 10.1186/s12893-025-02932-7. BMC Surg. 2025. PMID: 40329263 Free PMC article. Clinical Trial.
-
In vitro moxifloxacin drug interaction with chemotherapeutics: implications for retinoblastoma management.Exp Eye Res. 2014 Jan;118:61-71. doi: 10.1016/j.exer.2013.10.009. Epub 2013 Oct 22. Exp Eye Res. 2014. PMID: 24157270 Free PMC article.
-
Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections.Clin Ophthalmol. 2008 Mar;2(1):77-91. doi: 10.2147/opth.s1666. Clin Ophthalmol. 2008. PMID: 19668391 Free PMC article.
-
Two-photon microscopy of Paneth cells in the small intestine of live mice.Sci Rep. 2018 Sep 21;8(1):14174. doi: 10.1038/s41598-018-32640-7. Sci Rep. 2018. PMID: 30242205 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources